New board appointment at Rib-X
This article was originally published in Scrip
Rib-X Pharmaceuticals, a US development-stage company discovering and developing antibiotics for the treatment of antibiotic-resistant infections, has appointed Dr Joseph Amprey to its board of directors. He succeeds David Mott, who is continuing as an independent director of the company. Dr Amprey is senior managing director at MedImmune Ventures, a venture capital fund wholly owned by MedImmune. His appointment brings the number of Rib-X board members to 10.
You may also be interested in...
In an open letter to the European Commission, Parliament and Council presidents, more than 400 cosmetics companies and animal-rights groups accuse the European Chemicals Agency of effectively “shredding” the animal testing ban on cosmetics by requiring testing for certain chemicals under REACH.
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.